Fennec Nears Market For Chemo-Induced Hearing Loss in Children
Pedmark Filed in US and Europe
Cisplatin is very effective but two thirds of children treated with the drug for cancer are left with some hearing loss. If approved this year, Fennec's Pedmark could go some way to preventing that distressing side effect.
You may also be interested in...
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.